Treatment Patterns and Outcomes of Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in Tanzania
JCO Global Oncology · 2025
DOI: 10.1200/go-24-00612 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Global Oncology, 2025. Verfasst von Lemi Ndugumbi Zinga und 4 weiteren Autor:innen. Beteiligte Einrichtung: Muhimbili University of Health and Allied Sciences (MUHAS), Dar es Salaam, Tanzania. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: FIC NIH HHS.
Abstract (Originalsprache)
PURPOSE Human epidermal growth factor receptor 2 (HER2)–positive breast cancer (HER2+BC) is linked to poorer outcomes. Trastuzumab is the standard treatment, but its high cost limits access in resource-limited settings. This study evaluated the treatment patterns and survival outcomes of patients with HER2 BC in Tanzania. MATERIALS AND METHODS A retrospective hospital-based study was conducted between January 2018 and May 2021 at two prominent public tertiary hospitals in Tanzania. The primary outcome was the 5-year overall survival (OS) rate. Independent variables included demographics, clinical characteristics, and treatment patterns. Survival analysis was conducted using the Kaplan-Meier method. The log-rank test was used in univariate analysis, whereas multivariate Cox regression was used in multivariate analysis. RESULTS A total of 169 patients with nonmetastatic HER2+BC were included, with a median age of 50 years. Most patients were estrogen receptor–positive (50.3%) and diagnosed with stage III BC (58.6%). About 70.4% of patients received trastuzumab, whereas neoadjuvant chemotherapy was administered to 24.3%, and 95.9% underwent mastectomy. Trastuzumab was primarily used in the adjuvant setting rather than the neoadjuvant setting and was more accessible to patients with higher socioeconomic status. The 5-year OS was 65%, with a median survival of 72 months. Trastuzumab reduced the mortality risk by 74%. Extended therapy with trastuzumab benefited patients with hormone receptor–negative HER2+BC more than those who were hormone receptor–positive. Advanced-stage disease increased mortality risk, whereas postmenopausal status and nonsmoking were associated with lower mortality. A higher Eastern Cooperative Oncology Group score (>1) was associated with an increased mortality risk. CONCLUSION Trastuzumab significantly improves OS in resource-limited settings, particularly in patients with hormone receptor–negative HER2+BC. There are disparities in access to trastuzumab in Tanzania.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Muhimbili University of Health and Allied Sciences (MUHAS), Dar es Salaam, Tanzania.
- Ocean Road Cancer Institute (ORC), Dar es Salaam, Tanzania.
ORCID-Profile: Lemi Ndugumbi Zinga, Kelvin Mbelekwa, Mamsau Twalib Ngoma, Emmanuel L Lugina
Förderung
- FIC NIH HHS
Zitieren
APA
Zinga, L. N., Tarimo, Q. G., Mbelekwa, K., Ngoma, M. T., & Lugina, E. L. (2025). Treatment Patterns and Outcomes of Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in Tanzania. JCO Global Oncology. https://doi.org/10.1200/go-24-00612
Vancouver
Zinga LN, Tarimo QG, Mbelekwa K, Ngoma MT, Lugina EL. Treatment Patterns and Outcomes of Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in Tanzania. JCO Global Oncology. 2025. doi:10.1200/go-24-00612
BibTeX
@article{Zinga2025,
author = {Zinga, Lemi Ndugumbi and Tarimo, Queen Godfrey and Mbelekwa, Kelvin and Ngoma, Mamsau Twalib and Lugina, Emmanuel L},
title = {Treatment Patterns and Outcomes of Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in Tanzania},
journal = {JCO Global Oncology},
year = {2025},
doi = {10.1200/go-24-00612}
}
EUVIMED